Please assess the completion status of the following clinical trial:

Trial Title: A Randomized Phase II Study of Oral Sapacitabine in Patients With Advanced Cutaneous T-cell Lymphoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients with advanced CTCL~* Have had at least 2 systemic therapies~* Must have evaluable disease~* Eastern Cooperative Oncology Group performance status 0-2~* Adequate bone marrow, hepatic and renal function~* At least 3 weeks from prior therapies~* Not receiving topical steroids or have been on a stable dose of topical steroids for at least 2 weeks~* Able to swallow capsules~* At least 3 weeks from major surgery~* Agree to practice effective contraception~* Able to understand and willing to sign the informed consent form~Exclusion Criteria:~* Receiving systemic steroids~* Receiving topical or systemic retinoids or vitamin A~* Receiving radiotherapy, biological therapy,or any other investigational agents~* Uncontrolled intercurrent illness~* Pregnant or lactating women~* Known to be HIV-positive~* Active hepatitis B and/or hepatitis C infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A: High dose (Type: EXPERIMENTAL): High-dose (Arm A): 200 mg b.i.d. x 3 consecutive days per week for 2 weeks followed by 1-week rest
- Arm B: High dose (Type: EXPERIMENTAL): Low-dose (Arm B): 100 mg b.i.d. x 3 consecutive days per week for 2 weeks followed by 1-week rest

Based on this trial design, predict the completion outcome and termination type (if applicable).